Top Story Today
Gilead Bets $1.9 Billion on Cancer Drugs That Only Wake Up Inside Tumors
Gilead just signed a three-program deal worth up to $1.9 billion with Vir Biotechnology, paying $90 million upfront (including a $25 million equity stake at a 30% premium) for access to masked T-cell engagers that stay inert in healthy tissue and activate only when tumor enzymes strip off their molecular disguise. Vir handles early discovery; Gilead runs the clinical gauntlet from there. The deal fills a notable gap in Gilead's oncology portfolio and validates a masking approach that multiple pharma giants are now chasing, especially after CytomX's rival platform stumbled in Phase 1.
Why it matters: The deal is the clearest signal yet that masked T-cell engagers, drugs engineered to avoid the toxic side effects that have limited first-generation versions, are becoming pharma's next major oncology obsession. With AbbVie, Amgen, and now Gilead all placing bets in the space, the race to build a truly tumor-selective cancer immunotherapy is heating up fast.
Read more →Deals and M&A
GSK Spends $1 Billion on a Rare Cancer Most People Have Never Heard Of
GSK acquired IDRx for up to $1.15 billion ($1 billion upfront) to get velzatinib, a KIT inhibitor designed to target all clinically relevant mutations in gastrointestinal stromal tumors. The drug is in Phase 3 testing head-to-head against sunitinib, with a frontline study also underway. The deal fills a GI cancer gap in GSK's oncology rebuild.
Read more →Novartis Writes a $575 Million Check for RNA Tech That Turns Your Body Into a Drug Factory
Novartis paid $575 million upfront to license Abogen Biosciences' mRNA platform, in a deal worth up to $7.8 billion. The lead program delivers mRNA instructions that tell cells to build a T-cell engager for autoimmune disease. It's the largest upfront payment in a recent wave of RNA deals, signaling fierce competition for next-gen delivery technology.
Read more →Pfizer Drops $500 Million on a Protein Degradation Approach That Stops Bad Proteins Before They're Made
Pfizer signed a deal worth over $500 million with French startup Enodia Therapeutics, gaining access to Sec61 inhibitors that block disease-causing proteins from ever being assembled. It's Pfizer's third distinct bet in protein degradation, alongside PROTACs (with Arvinas) and molecular glues (with Triana), building a diversified portfolio in one of pharma's hottest fields.
Read more →Zealand Bets $1.2 Billion That AI Can Design the Next Obesity Drug From Scratch
Zealand Pharma is paying up to $1.2 billion ($30 million upfront) to let Generate Biomedicines use generative AI to design entirely novel multispecific proteins for obesity. Instead of optimizing existing molecules, the platform creates proteins nature never imagined, targeting multiple metabolic pathways simultaneously. It's a frontier bet in an increasingly crowded weight-loss market.
Read more →Clinical and Regulatory
Keytruda's $32 Billion Monopoly Just Got Its First FDA Challenger
The FDA accepted the first-ever biosimilar application for Keytruda, the world's top-selling drug at $31.7 billion in annual sales. Formycon and Zydus filed FYB206 after clinical data showed pharmacokinetic equivalence, with a decision expected by Q3 2027. At least a dozen competitors are lining up behind them, though Merck's patent fortress could delay launches until the late 2020s or beyond.
Read more →FDA Panels Votes 10-1 Against Otsuka's PTSD Combination Therapy
FDA advisors voted 10-1 that Otsuka failed to prove its Rexulti-sertraline combination works for PTSD, and the agency followed with a Complete Response Letter denying the application. It would have been the first new PTSD drug since 2001. Otsuka acquired Transcend Therapeutics to take another shot through a different mechanism.
Read more →Syndax Scraps IPF Program After Phase 2 Miss, Stock Drops 15%
Syndax killed its idiopathic pulmonary fibrosis program after axatilimab failed to slow lung function decline in Phase 2. The exit reshapes a messy IPF landscape where BMS's admilparant just posted mixed Phase 3 results and Boehringer's nerandomilast recently won approval. Syndax says it's fully funded through profitability on its existing oncology franchise.
Read more →Industry Watch
Another Oral GLP-1 Bites the Dust (and It Won't Be the Last)
Verdiva Bio killed a Phase 2 weight-maintenance trial after enrolling 8 patients, not for safety reasons but because the oral GLP-1 market got too crowded. They join Pfizer, Terns, and others who've retreated from undifferentiated obesity programs. Verdiva is pivoting toward a GLP-1/amylin combination strategy to stand out from the giants.
Read more →Sanofi Settles EU Probe Over Trash-Talking a Rival's Flu Vaccine
Sanofi avoided a potentially massive EU fine by agreeing to stop disparaging CSL Seqirus's flu vaccine Fluad in France and Germany. The settlement includes corrective statements and marketing restrictions lasting until 2030. It's the latest in a growing line of cases where European regulators treat pharma marketing tactics as competition law violations.
Read more →